EU-funded R&D project

Promoting early identification and improving outcomes for patients with psoriatic arthritis

HIPPOCRATES is a research project which aims at promoting early identification and improving outcomes for patients with psoriatic arthritis. By looking into the disease mechanisms of psoriatic arthritis, the 26 European partners collaborating in HIPPOCRATES aim at improving diagnostic and therapeutic options for patients living with this condition.

Through gaining a better understanding of the complex interplay between clinical and environmental factors, genotype and molecular pathways, the team aims to enable earlier diagnosis and a more accurate prediction of disease progression. This will revolutionise treatment and deliver profound patient benefits. The HIPPOCRATES partners contribute a diverse range of backgrounds including clinical, scientific, data analytics, ethics, patient participation as well as SME and pharmaceutical industry expertise. 

Data management

In order to achieve its goals, the HIPPOCRATES project will set up a single integrated database combining the cohorts and datasets of the most important European PsA studies and establish a Europe-wide library of relevant clinical biosamples. HIPPOCRATES will also establish a large, prospective, observational study of 25,000 patients with psoriasis who will be recruited and followed on-line for development of PsA.

i~HD has responsibility for ensuring robust data protection, data management and FAIR data sharing.

The project runs for a period of five years, starting in June 2021, with a total budget of EUR 21 million provided by the Innovative Medicines Initiative (IMI 2), a Joint Undertaking of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Consortium Partners

Academisch Medisch Centrum Bij De Universiteit Van Amsterdam, ATTUROS Limited, Biopharma SRL, Consorci Institut D’investigacions Biomediques August Pi I Sunyer, Eurice – European Research and Project Office Gmbh, European League Against Rheumatism, Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung e.V., Katholieke Universiteit Leuven, Kungliga Tekniska Hoegskolan, National University of Ireland Dublin (UCD), Novartis Pharma AG, Rigshospitalet, SIB Institut Suisse de Bioinformatique, Stichting Group for Research and Assessment of Psoriasis and Psoriatic Arthritis EU, The European Institute for Innovation through Health Data, UCB, Università Cattolica Del Sacro Cuore, Universitaetsklinikum Erlangen, VIB VZW

Supported by